PE20080850A1 - Agentes que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
PE20080850A1
PE20080850A1 PE2007001212A PE2007001212A PE20080850A1 PE 20080850 A1 PE20080850 A1 PE 20080850A1 PE 2007001212 A PE2007001212 A PE 2007001212A PE 2007001212 A PE2007001212 A PE 2007001212A PE 20080850 A1 PE20080850 A1 PE 20080850A1
Authority
PE
Peru
Prior art keywords
methyl
hydroxy
compounds
cyane
dioxo
Prior art date
Application number
PE2007001212A
Other languages
English (en)
Spanish (es)
Inventor
Lutz Lehmann
Ananth Srinivasan
Thomas Brumby
Detlef Sulzle
Timo Stellfeld
Keith Graham
Mylene Karramkam
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of PE20080850A1 publication Critical patent/PE20080850A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
PE2007001212A 2006-09-08 2007-09-10 Agentes que comprenden compuestos marcados con 18f y metodos relacionados PE20080850A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
PE20080850A1 true PE20080850A1 (es) 2008-09-02

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001212A PE20080850A1 (es) 2006-09-08 2007-09-10 Agentes que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2279759A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2858907A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2717985A4 (en) * 2011-06-09 2015-02-25 Ge Healthcare Ltd DEVICE AND METHOD FOR DISTILLATION
CN108558939B (zh) * 2013-03-15 2021-08-24 癌靶技术有限责任公司 18f-标记的靶向psma的pet成像剂
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
MA49767A (fr) 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
US20210238124A1 (en) * 2018-04-20 2021-08-05 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
CA3127689A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
EP4692065A1 (en) 2023-03-31 2026-02-11 Nissan Chemical Corporation Pyrazole compound and harmful organism control agent

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1990003980A1 (en) * 1988-10-14 1990-04-19 Administrators Of The Tulane Educational Fund Therapeutic peptides
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
ES2248084T3 (es) * 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US7115766B2 (en) * 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497316B1 (en) 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
JP2009505962A (ja) 2005-07-29 2009-02-12 バイエル・ヘルスケア・エルエルシー 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Also Published As

Publication number Publication date
EP2063918A2 (en) 2009-06-03
MA30780B1 (fr) 2009-10-01
EP2455105A3 (en) 2012-09-05
IL211033A0 (en) 2011-04-28
CA2858907A1 (en) 2008-03-13
CA2662449A1 (en) 2008-03-13
NO20091428L (no) 2009-06-03
IL211527A0 (en) 2011-05-31
IL211526A0 (en) 2011-05-31
US20080292548A1 (en) 2008-11-27
JP2014028813A (ja) 2014-02-13
JP5603074B2 (ja) 2014-10-08
EP2455105B1 (en) 2016-02-17
KR20090058553A (ko) 2009-06-09
TW200829277A (en) 2008-07-16
AR062726A1 (es) 2008-11-26
EP2279759A3 (en) 2013-04-17
EP2063918B1 (en) 2014-02-26
CO6150196A2 (es) 2010-04-20
JP2010503618A (ja) 2010-02-04
RU2009112716A (ru) 2010-10-20
EP2289564A3 (en) 2012-11-14
EP2455105A2 (en) 2012-05-23
AU2007294124A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
IL197363A0 (en) 2011-08-01
CL2007002620A1 (es) 2008-05-30
US8557776B2 (en) 2013-10-15
BRPI0716554A2 (pt) 2013-09-24
EP2289564A2 (en) 2011-03-02
MX2009002492A (es) 2009-08-28
WO2008028688A2 (en) 2008-03-13
CR10654A (es) 2009-04-14
TN2009000063A1 (en) 2010-08-19
EP2279759A2 (en) 2011-02-02
JP5722966B2 (ja) 2015-05-27
WO2008028688A3 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
PE20080850A1 (es) Agentes que comprenden compuestos marcados con 18f y metodos relacionados
AR051839A1 (es) Metodo para preparar n-fenilpirazol -1- carboxamidas
PE20100809A1 (es) Inhibidores de glutamato de metaloproteinasas de matriz y agrecanasas
ES2494442T3 (es) Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico
AR057987A1 (es) Compuestos agonistas de cb1 (receptor cannabinoide)
RU2370485C2 (ru) Амидоацетонитрильные производные
BRPI0601896A (pt) composições que contêm microgéis e agentes espessantes
AR072099A1 (es) Compuestos para modulacion de cinasas
PE20090218A1 (es) Compuestos mimeticos de glucocorticoides, metodos de preparacion y composiciones farmaceuticas
PE20040374A1 (es) DERIVADOS DE ACIL-4-CARBOXIFENILUREA COMO INHIBIDORES DE LA GLUCOGENO FOSFORILASA a
MA31763B1 (fr) Inhibiteurs de kinase de type polo
CY1109898T1 (el) Τεταρτοταγεις ενωσεις αμμωνιου και η χρηση τους ως αντιμουσκαρινικοι παραγοντες
AR066793A1 (es) Agentes de 3- ciano-4-triazolil fenilsoxazolina para el control de plagas de invertebrados
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
PE20040892A1 (es) Antagonistas del receptor muscarinico m3 de acetilcolina
AR043049A1 (es) Derivados de hidantoina, proceso de preparacion del mismo y composicion farmaceutica
PE20140381A1 (es) Dispersiones solidas extruidas por fusion que contienen un agente inductor de apoptosis
AR063449A1 (es) Proceso quimico para derivados de quinazolina, intermediarios
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
PE20090758A1 (es) Un proceso para la preparacion de compuestos de aminodiol protegidos con oxazolina, utiles como intermediarios para florfenicol
NO20076018L (no) Lagringsstabile opplosninger av optiske hvitemidler
PE20060427A1 (es) Derivados de pirazol como inhibidores de la union del glucagon y composiciones
AR063906A1 (es) Compuestos quimicos derivados del indazol, una composicion farmaceutica y procesos de prpeparacion de los compuestos
PE20140792A1 (es) Composiciones farmaceuticas
BR112022013547A2 (pt) Métodos para potencializar a farmacocinética, para aumentar a concentração plasmática e a vigília ou diminuir a sonolência excessiva, e, composição

Legal Events

Date Code Title Description
FC Refusal